$PSNL

Tachibana Aaron sold $449K of PSNL

Tachibana Aaron (CFO AND COO) sold 38,799 shares of Personalis, Inc. (PSNL) at $11.58 ($0.45M total) on 2026-05-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tachibana Aaron
Published May 30, 2026, 12:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 30, 2026, 12:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
medium confidence
Mentioned
$PSNL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

Because the plan is pre-arranged, the sale is generally less informative about near-term company outlook; it mainly provides a sentiment datapoint.

02

Market read

Insider selling disclosure for PSNL; likely low incremental trading edge absent other catalysts.

03

What to watch

Check whether there were concurrent insider buys/sales by other officers/directors and whether the sale size is unusual versus prior Form 4 activity.

Relevance 6/10Novelty 4/10Timing: Filed after-hours on 2026-05-29 (20:27:08-04:00).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by the company’s CFO/COO under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$PSNLNeutralMedium confidence
Context

Personalis CFO/COO Tachibana Aaron sold 38,799 PSNL shares for about $449K under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited/short-lived impact; watch for follow-on insider activity or unusual volume rather than expecting a directional move.

Evidence & confidence

The filing is a Form 4 open-market sale conducted under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal; single-company insider transaction with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

A 10b5-1 sale can reflect routine liquidity planning rather than bearish expectations, so price reaction may be overstated.

Key entities

  • Personalis, Inc.

    Issuer of the insider transaction; CFO/COO sold shares under a 10b5-1 plan.

  • Tachibana Aaron

    CFO AND COO who executed the reported open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.